Menu

30/11/2020

The UCA of Dr. Mikel Sánchez and the BIOARABA Health Research Institute sign the collaboration agreement on research, development of new diagnostic products and treatments and experimental means

The main objective of the agreement is to collaborate in the promotion of in vitro diagnostic products research, as well as in the development of therapeutic products that have to do with restorative and regenerative medicine and the development of diagnostic and therapeutic equipment.

The Arthroscopic Surgery Unit of Dr. Mikel Sánchez (UCA, according to the Spanish acronym) and the BIOARABA Health Research Institute have signed a collaboration agreement with the aim of regulating a framework for collaboration in the field of research and development of new diagnostic products and treatments, as well as the research for the optimization of these tools.

The UCA is a private entity whose main objectives are the diagnosis and the medical/ orthopedic treatment of the different pathologies related to the locomotor system. Traumatology, Orthopaedic Surgery and Arthroscopic Surgery of different joints; the design, research, development and commercialization of regenerative techniques, as well as products, instruments and medical systems, the iconography of animal and human anatomy and the training of professionals who use products and carry out their techniques, so that these products and techniques developed by UCA as a result of its research to be used appropriately.

BIOARABA is one of the three Health Research Institutes in the Basque Country whose main objective is to promote biomedical, epidemiological, public health and health services research; In addition, it substantiates scientifically the programs and policies of the health system; and permanently promotes translational research, being its scope of action the Historical Territory of Araba / Álava.

The common interest actions to be carried out are those ones related to the field of research and the development of new diagnostic products and treatments, as well as the research to optimize these tools. Among them we can highlight the development of in vitro diagnostic products, the development of therapeutic products in the area of restorative and regenerative medicine and the development of diagnostic and therapeutic equipment that may be useful for the development of their projects and potential clinical applications of these ones, etc.

It will be a 4-year agreement, and after that time, the parties may expressly renew the agreement for a further 4 years.